James Coffin - Jul 22, 2021 Form 4 Insider Report for Sema4 Holdings Corp. (WGSWW)

Role: President and COO
Signature: /s/ Daniel Clark, Attorney-in-Fact
Stock symbol: WGSWW
Transactions as of: Jul 22, 2021
Transactions value $: $0
Form type: 4
Date filed: 7/26/2021, 06:53 PM
Next filing: Oct 5, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	WGSWW	Employee Stock Option (Right to Buy)	Award	+2.17M	2.17M	Jul 22, 2021	Class A Common Stock	2.17M	$0.15	Direct	F1, F2
transaction	WGSWW	Employee Stock Option (Right to Buy)	Award	+333K	333K	Jul 22, 2021	Class A Common Stock	333K	$0.77	Direct	F1, F2
transaction	WGSWW	Employee Stock Option (Right to Buy)	Award	+481K	481K	Jul 22, 2021	Class A Common Stock	481K	$0.77	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F2	Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

Content

6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

Remarks:

The merger agreement provides that certain former stockholders and equity award holders of Sema4 will receive additional shares of the Issuer's Class A common stock and awards of restricted stock units upon the achievement of certain vesting conditions.